Falco Holdings Co Ltd operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Falco Holdings Co Ltd with three other
pharmaceutical manufacturers in Asia:
Dr. Lal PathLabs Ltd
sales of 7.91 billion Indian Rupees [US$120.83 million]
Thyrocare Technologies Ltd
(2.41 billion Indian Rupees [US$36.80 million]
of which 89%
was Diagnostic Testing Services), and
Medical & Biological Laboratories Company Limited
(8.06 billion Japanese Yen [US$71.46 million]
of which 99%
was Reagent business).
Falco Holdings Co Ltd reported sales of ¥48.73 billion (US$432.21 million)
March of 2016.
increase of 4.6%
versus 2015, when the company's sales were ¥46.59 billion.
Despite this increase, sales are still
below the level achieved in 2014, when Falco Holdings Co Ltd
reported sales of ¥58.40 billion.
Sales of Preparation of Drugs saw an increase
that was more than double the company's growth rate: sales were up
12.4% in 2016, from
¥17.88 billion to ¥20.09 billion.
Not all segments of Falco Holdings Co Ltd experienced an increase in sales in 2016:
sales of Medical Test fell 0.3% to ¥28.64 billion.